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Circulating malignant Sezary cells are a clonal proliferation of CD4þCD45ROþ T lymphocytes primarily involving
the skin. To study the biology of these malignant T lymphocytes, we tested their ability to migrate in chemotaxis
assays. Previously, we had shown that the neuropeptide neurotensin (NT) binds to freshly isolated Sezary
malignant cells and induces through NT1 receptors the cell migration of the cutaneous T cell lymphoma cell line
Cou-L. Here, we report that peripheral blood Sezary cells as well as the Sezary cell line Pno fail to migrate in
response to neurotensin although they are capable of migrating to the chemokine stromal-cell-derived factor 1a.
This is in contrast with normal circulating CD4þ or CD8þ lymphocytes, which respond to both types of
chemoattractants except after ex vivo short-time anti-CD3 monoclonal antibody activation, which abrogates the
neurotensin-induced lymphocyte migration. Furthermore, we demonstrate that neurotensin-responsive T
lymphocytes express the functional NT1 receptor responsible for chemotaxis. In these cells, but not in Sezary
cells, neurotensin induces recruitment of phosphatidylinositol-3 kinase, and redistribution of phosphorylated
cytoplasmic tyrosine kinase focal adhesion kinase and ﬁlamentous actin. Taken together, these results, which
show functional distinctions between normal circulating lymphocytes and Sezary syndrome cells, contribute to
further understanding of the physiopathology of these atypical cells.
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Neurotensin (NT), a tridecapeptide, is biologically active in
the central nervous system, where it binds with high affinity
to neuronal receptors (Carraway and Leeman, 1973; Kitabgi
et al, 1977). Two types of NT receptors have been identified,
NT1 and NT2 receptors, which are G-protein-coupled
receptors (Vita et al, 1993; 1998; Chalon et al, 1996). NT1
receptors bind NT with high affinity and are antagonized by
nonpeptide antagonists such as the 2-(1-(7-chloroquinolin-
4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carbonyl)ami-
no)-adamantane-2-carboxylic acid (SR48692) (Gully et al,
1993, 1997). NT1 receptor engagement activates guanine
nucleotide-binding subunits (Gq), inducing phosphatidyli-
nositol turnover and protein kinase C activation. In contrast,
it has been found that triggering NT2 receptor by NT does
not induce biologic responses, although nonpeptide NT1
receptor antagonists are potent agonists (Vita et al, 1998).
Recently, the gp95/sortilin has also been found to bind NT.
This receptor is structurally different from the two G-protein-
coupled NT1 and NT2 receptors, however, and is similar to
the mannose 6-phosphate receptor bearing a single
transmembrane domain (Mazella et al, 1998).
It is now well established that nervous, endocrine, and
immune systems constitute a totally interconnected circuit
via hormones and neuropeptides (Savino and Dardenne,
1995). Several neuropeptides including NT have been
reported to modulate immune responses (Johnston et al,
1994; De la Fuente et al, 1998; Scholzen et al, 1998;
Delgado et al, 1999), to alter the growth of cancer cells, and
to increase small lung cancer colony formation (Davis et al,
1991). In addition, high and low affinity NT receptors were
described in peripheral blood mononuclear cells (PBMC)
and in leukemic T cell lines that were capable of triggering
functional responses upon engagement with the physiolo-
gic ligand (Evers et al, 1994).
Cutaneous T cell lymphomas (CTCL) are a heteroge-
neous group of lymphomas primarily involving the skin.
They include an indolent group of lymphomas with mycosis
fungoides and its variants, which are characterized by skin
invasion of a clonal proliferation of T CD4þ lymphocytes
that phenotypically resemble mature T helper lymphocytes.
CD30þ T cell proliferation is another group of indolent T
lymphomas characterized by a favorable evolution with a
tendency to spontaneous regression. Finally, an aggressive
group includes Sezary syndrome with the presence of
circulating malignant T cells, transformed mycosis fun-
goides, and CD30-negative pleiomorphic CTCL (Willemze
et al, 1997). In order to understand the physiopathology of
CTCL and to determine biologic responses different from
those of normal T lymphocytes, we have investigated the1The first two authors contributed equally to this work.
Abbreviations: F-actin, filamentous actin; FAK, focal adhe-
sion kinase; NT, neurotensin; PBMC, peripheral blood
mononuclear cell; PI-3K, phosphatidylinositol-3 kinase;
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NT-induced migration of an interleukin-2 (IL-2) dependent,
long-term cultured CTCL cell line (Ramez et al, 2001). In this
study, we extend these previous findings by studying the
ability of NT to induce the migration of freshly isolated
peripheral blood Sezary cells and normal T lymphocytes,
which were both found to bind NT (Ramez et al, 2001). We
report that nonseparated as well as CD4þ circulating cells
isolated from different Sezary syndrome patients with
various percentages of malignant cells were consistently
unable to migrate in response to NT. In contrast, PBMC
including separated CD4þ or CD8þ lymphocytes isolated
from normal individuals responded to the chemoattractant
effect of NT. We found that short-time anti-CD3 monoclonal
antibody activation rendered normal T lymphocytes unable
to migrate in response to NT, however. The lack of the
chemoattractant effect of NT on Sezary cells was not
attributable to an alteration in the cell migration signaling
pathways as they migrate in response to chemokines such
as stromal-cell-derived factor 1a (SDF-1a). It is well known
that cell migration induces changes that occur at focal
adhesion plaques, which are cell/extracellular matrix con-
tact points containing integrin receptors, cytoskeletal
components, and intracellular signaling proteins such as
focal adhesion kinase (FAK) (Clark and Brugge, 1995).
Therefore, it was important to determine whether NT
induced FAK redistribution in malignant Sezary T lympho-
cytes. Interestingly, we found that the Sezary cell line Pno,
which expresses significant amounts of NT1 receptors, was
not only refractory to cell migration to NT but also failed to
induce a redistribution of (Tyr397)-phospho-FAK. Moreover,
in NT-responsive T lymphocyte lines, we found that the NT1
receptor was responsible for the NT-induced chemotaxis by
recruiting the phosphatidylinositol-3 kinase (PI-3K) and by
inducing the translocation of (Tyr397)-phospho-FAK and
redistribution of filamentous actin (F-actin). As NT1 receptor
is similarly expressed in both NT-refractory and NT-
responsive cell lines, these data suggest that this receptor
is anergized in Sezary cells. Overall, these results indicate
that NT, which is a chemoattractant for circulating T
lymphocytes isolated from normal individuals, fails to
induce the migration of Sezary patient PBMC, and thus
does not play a role in homing and distribution of these
cells.
Results
NT fails to induce migration of circulating Sezary cells
whereas it induces migration of lymphocytes isolated
from normal individuals To extend our studies, which
previously showed that NT is a potent chemoattractant for
an IL-2-dependent CTCL cell line termed Cou-L (Ramez et
al, 2001), we tested whether NT was a chemoattractant for
lymphocytes isolated from the blood of patients with
various percentages of circulating atypical cells. We found
that NT did not induce migration of the circulating mono-
nuclear cells in five representative Sezary syndrome
patients expressing from 90% to 20% of Sezary cells
(Fig 1A, upper left panel). The lack of NT-induced PBMC
migration was observed with various concentrations of the
neuropeptide from 10 nM to 1 mM (data not shown). In
contrast, patients’ PBMC were capable of migrating in
response to the chemokine SDF-1a (100 ng per mL), as
shown for the representative patient PBMC BAR (Fig 1A,
upper right panel). To further establish that Sezary lympho-
cytes responded differentially to NT and to SDF-1a, we
tested freshly isolated circulating CD4þ lymphocytes from a
patient with 90% atypical circulating lymphocytes and the
previously described Pno malignant Sezary cell line
established from the PBMC of a patient (Poszepczynska
et al, 2000). The results show that both the freshly isolated
CD4þ lymphocytes (Fig 1A, lower left panel) and the cell line
Pno (Fig 1A, lower right panel) failed to migrate in response
to NT, whereas they migrated towards SDF-1a. Taken
together, these results indicate that PBMC or purified
CD4þ isolated from Sezary patients were unable to
migrate toward NT, whereas they migrated to the chemokine
SDF-1a.
In parallel with the experiments performed with Sezary
patient PBMC, we tested the chemotactic effects of NT on T
lymphocytes isolated from normal individuals. We found
that NT induced migration of normal individual PBMC at an
optimum concentration of 400 nM, with individual variations
in the level of NT-induced chemotaxis (Fig 1B, upper left
panel). Interestingly, NT was just as efficient as the
chemokines SDF-1a, RANTES, or fractalkine at inducing
mononuclear cell migration (Fig 1B, upper right panel). We
then investigated whether NT was active on both CD8þ and
CD4þ lymphocytes as well as on monocytes. The repre-
sentative results presented in Fig 1(B) (lower left panel)
indicate that both T lymphocyte subsets were responsive to
the chemotactic effects of NT. We often obtained a greater
number of migrating cells with the CD8þ T lymphocyte
subset, however. In contrast, monocytes were consistently
refractory to the chemotactic effect of NT alone. We next
tested whether, upon anti-CD3 monoclonal antibody activa-
tion, PBMC were capable of migrating in response to NT
and found that NT did not induce migration of such short-
time anti-CD3 monoclonal-antibody-activated PBMC,
although they migrated towards the chemokine SDF-1a.
NT1 receptor transcript is similarly expressed by
lymphocytes isolated from both normal individuals
and Sezary patients We previously reported that Sezary
lymphocytes, delineated with specific anti-TCRVb mono-
clonal antibodies, were capable of binding NT labeled with
fluorescein isothiocyanate (FITC) and thus expressed NT
receptors at their cell membrane (Ramez et al, 2001). Here,
we further extended our studies by determining if NT1
receptor transcripts were similarly detectable in normal
PBMC and Sezary syndrome PBMC. The results presented
in Fig 2 indicate that NT1 receptor transcripts are present in
PBMC from two representative Sezary syndrome patients
with 90% CD4þ circulating T lymphocytes as well as in
CD4þ isolated circulating lymphocytes from a normal
individual. In addition, the Jurkat cell line as well as isolated
circulating CD8þ from a normal individual express NT1
receptor transcripts. Interestingly, the Sezary cell line Pno
and separated monocytes that failed to migrate in response
to NT alone also expressed NT1 receptor transcripts. These
results indicate that the failure of Sezary PBMC to migrate in
response to NT stimulation is not attributable to the lack of
NT1 receptor transcription.
112 MAGAZIN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
The chemotactic effect of NT on T lymphocytes occurs
through NT1 receptor and is inhibited by phosphoinosi-
tide 3-kinase inhibitors In order to determine whether the
chemotactic effect of NT on T lymphocytes was attributable
to NT1 receptor, the effect of the NT1 receptor antagonist
SR48692 on NT-induced migration of the T lymphocyte line
Figure 1
Chemotaxis of circulating lymphocytes isolated from Sezary patients and normal individuals. After migration in a Transwell assay, cells in the
upper and lower chambers were enumerated in a microscope. Each experiment was done in triplicate and the results are presented as the mean
percentage of cells migrating with NT or chemokinesþSD compared with vehicle controls (100% migration). (A) Upper left panel: Freshly isolated
PBMC from five different Sezary syndrome patients were tested for NT-induced chemotaxis. Cells were placed in the upper chambers and allowed
to migrate in response to 400 nM NT or to vehicle alone for 12 h. The experiments were done in parallel with cells of normal individuals. Upper right
panel: PBMC from a Sezary syndrome patient were tested for their ability to migrate in response to SDF-1a (100 ng per mL) or NT (400 nM). Lower
panels: The Sezary cell line Pno (right) and separated CD4þ cells isolated from a Sezary syndrome patient (left) were tested for their chemotactic
responses to NT (400 nM), SDF-1a (100 ng per mL), or vehicle alone. (B) Upper left panel: NT-induced migration of PBMC isolated from five different
normal individuals. Cells were placed in the upper chambers and allowed to migrate in response to 400 nM NT or to vehicle alone for 12 h. Upper
right panel: Migration of PBMC from a normal individual in response to RANTES (100 ng per mL), SDF-1a (100 ng per mL), neurotactin/fractalkine (40
ng per mL), or NT (400 nM). Lower left panel: Migration of separated CD4þ , CD8þ , and CD14þ cells in response to NT or vehicle. Lower right panel:
Migration of anti-CD3 monoclonal antibody-activated PBMC to NT, SDF-1a, or vehicle alone.
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Jurkat was tested. These cells express significant amounts
of NT1 receptor transcripts (Fig 2) and low amounts of NT2
receptor and gp95/sortilin transcripts (data not shown). A
representative experiment, which indicates that NT induced
strong migration of Jurkat cells and that this migration was
inhibited in a dose-dependent manner by SR48692, is
shown in Fig 3(A). The nonpeptide NT1 receptor antagonist
alone had no effect on the spontaneous cell migration
obtained with medium alone (data not shown). Next, in
order to investigate the signaling responsible for chemo-
taxis by NT, we tested whether the use of PI-3K inhibitors
would affect the lymphocyte migration. For this purpose we
used the CTCL cell line Cou-L previously found to express
functional NT1 receptors (Ramez et al, 2001). Pretreatment
of Cou-L with either LY294002 (50 mM) or wortmannin (100
nM) strongly inhibited the NT-induced Cou-L migration,
which was also inhibited by the nonpeptide NT1 receptor
antagonist SR48692 (Fig 3B). Taken together, these results
indicate that NT induces chemotaxis via the NT1 receptor,
which recruits PI-3K.
NT1 receptor engagement in Cou-L cells induces a
redistribution of phosphorylated FAK and F-actin We
tested the hypothesis that NT1 receptor triggering results in
the translocation of phospho-FAK, FAK being one of the
major substrates for integrin-dependent tyrosine phosphor-
ylation. We used an antibody specific for (Tyr-397)-phos-
phorylated FAK to show that phospho-FAK is diffusely
distributed in the Cou-L cell line untreated with NT but is
significantly redistributed towards the cell periphery in
response to 5 or 10 min incubation in the presence of NT
at all the concentrations tested. A representative experi-
ment of the response of Cou-L cells to 200 nM NT is shown
in Fig 4(A). Furthermore, we found that phospho-FAK
translocation was dependent on the NT1 receptor and PI-
3K recruitment, as it was inhibited by SR 48692 and by the
PI-3K inhibitors LY294002 (Fig 4A) and wortmannin (data
not shown). We also observed that NT induced F-actin
redistribution accompanied by the formation of feather-like
projections on the periphery of Cou-L cells (Fig 4B).
Interestingly, we observed no translocation of phospho-
FAK (Fig 5) or F-actin (data not shown) in response to NT in
the Sezary cell line Pno, which did not migrate in response
to NT (see Fig 1A, lower right panel). Finally, it should be
mentioned that NT was also able to relocalize phospho-FAK
and F-actin in the leukemic T cell line Jurkat in a way similar
to that described above (data not shown).
Taken together, these results suggest that NT1 receptor
signaling in resting normal T lymphocytes induces chemo-
taxis via PI-3K and a relocalization of phospho-FAK and F-
actin. Such signaling pathways do not appear to be
activated in the circulating malignant Sezary cells, as shown
by the absence of phospho-FAK redistribution in Pno cells
treated with NT (Fig 5).
Discussion
Functional NT receptors have been described in various
tumor cell lines derived from colonic adenocarcinomas
(Amar et al, 1986; Iwase et al, 1996; Ehlers et al, 1998), small
cell lung carcinomas (Woll and Rozengurt, 1989), prostate
adenocarcinomas (Carraway and Mitra, 1998; Mitra and
Carraway, 1999), and leukemias (Choi et al, 1999). Recently,
we reported that PBMC isolated from both normal
individuals and Sezary patients specifically bound NT. In
addition, as a functional consequence of this NT binding to
lymphocytes, we demonstrated with an IL-2-dependent
CTCL cell line that the neuropeptide interfered with the
growth induced by cytokines and promoted chemotaxis
Figure 2
NT1 receptor expression in PBMC isolated from normal individuals
and from Sezary syndrome patients and in several established cell
lines. RNA was extracted from cells and reverse transcribed into cDNA;
the amplification was performed using primers for NT1 receptor.
Figure3
Inhibition of NT-induced cell migration by the NT1 receptor
antagonist SR48692 and by PI3-K inhibitors. (A) NT-induced Jurkat
cell migration is triggered through the NT1 receptor. Jurkat cells were
preincubated with SR48692 (250 or 500 nM) for 30 min or with medium
and were then added in the upper chambers to assay NT-induced
migration. (B) The CTCL cell line Cou-L was preincubated with either
SR48692 or one of the PI3-K inhibitors for 30 min and was then added
in the upper chambers for the migration tests. The experiment was
done in triplicate and the results are presented as the mean percentage
of cells migrating with NTþSD compared to vehicle controls (defined
as 100% migration). Similar spontaneous migration with medium-only
was obtained with Cou-L incubated individually with SR48692 or the
PI3-K inhibitors.
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(Ramez et al, 2001). Here, we extended the latter functional
study with freshly isolated nonseparated as well as CD4þ
separated Sezary cells. We found that, unlike normal
PBMC, lymphocytes isolated from Sezary patients fail to
respond to NT-induced chemotaxis. Previous reports have
indicated that NT stimulates the adherence and the
chemotactic capacities of normal murine peritoneal lym-
phocytes (Garrido et al, 1992). We found that NT induced
lymphocyte migration from both CD4þ and CD8þ pheno-
types, whereas anti-CD3-activated PBMC did not migrate in
response to NT. Sezary cells therefore behave like activated
T lymphocytes, which is in accordance with their expression
of some early T cell activation markers (Dorfman and
Shahsafaei, 2002). Interestingly, NT-induced PBMC chemo-
taxis was as efficient as the response to chemokines such
as RANTES, fractalkine, and SDF-1a. It should be noted
that freshly isolated monocytes (CD14þ PBMC) failed to
migrate to NT although a previous report indicated that the
leukemic monocytic cell line U937 responds to NT through
NT1 receptors (Choi et al, 1999). The lack of NT-induced
migration of monocytes was not attributable to the absence
of NT1 receptors as a large amount of specific transcripts
was detected. Furthermore, the refractory response to NT
did not result from an alteration of cell function, as the
separated CD14þ monocytes were capable of migrating in
response to the chemokine MCP-3 (data not shown). We
found that peripheral blood lymphocytes, including CD4þ
and CD8þ , expressed NT1 receptor transcripts and that the
protein product accounted for the NT-induced chemotaxis,
as the NT1 receptor nonpeptide antagonist SR48692 was an
efficient inhibitor (data not shown). It is important to
emphasize that in the leukemic T cell line Jurkat, which
expresses transcripts of NT1 and NT2 receptors as well as
the transcripts of gp95/sortilin receptor, only the NT1
receptor is responsible for cell migration. We found that
NT, unlike the chemokine SDF-1a, is incapable of inducing
anti-CD3-activated lymphocyte chemotaxis. It is able to
induce the migration of cytokine-activated lymphocytes,
however, as observed with the IL-2-dependent CTCL line
Cou-L and normal PBMC activated with IL-2 (data not
shown). Thus, these results suggest that the absence of NT-
induced migration observed for anti-CD3-activated lym-
phocytes is rather specific to the CD3 triggering pathway
that inhibits the migration signaling pathway through NT1
receptors but not through CXCR4/CD184 (SDF-1a recep-
tor). It is important to mention that not only NT, but also
vasoactive intestinal polypeptide, is incapable of inducing
anti-CD3 monoclonal-antibody-activated lymphocyte mi-
gration (Johnston et al, 1994). We previously reported that
the cytokine-dependent Sezary cell line Pno as well as
freshly isolated peripheral blood Sezary cells were capable
of binding significant amounts of FITC-labeled NT (Ramez
et al, 2001). Here, we report that even though both types of
cells express significant amounts of NT1 receptor tran-
scripts, they are unresponsive to NT-induced migration,
although they migrate in response to CXCR4/CD184
triggering. This suggests that peripheral blood Sezary
malignant cell signaling through NT1 receptors, which leads
to cell migration, is anergized compared with circulating
lymphocytes isolated from normal individuals. Importantly,
we found that although the patients had various percen-
tages of malignant T cells, no NT-induced migration was
observed with any of these samples. Thus, it seems that the
nonmalignant T cells in Sezary patients do not behave as
peripheral blood lymphocyte T isolated from normal
individuals and therefore cannot be considered as normal
Figure 4
Redistribution of (Tyr-397)-phosphory-
lated FAK and F-actin in Cou-L cells
treated with NT. (A) Cells were treated
for 10 min with NT (200 nM) or vehicle
and stained for phosphorylated (Tyr-397)
FAK. Where indicated, cells were pre-
incubated with SR48692 or LY294002.
The experiment was done as indicated
in Materials and Methods and is repre-
sentative of five different experiments.
(B) Cells were stimulated for 5 min with
200 nM NT or vehicle and F-actin was
stained with BODIPY-phallacidin as de-
scribed in Materials and Methods.
Figure 5
Failure of NT to induce a redistribution of (Tyr-397)-phosphorylated
FAK in the Sezary cell line Pno. Cells were treated for 10 min with NT
(200 nM) or vehicle and stained for phosphorylated (Tyr-397) FAK. The
experiment was done in parallel with Cou-L and is representative of five
different experiments.
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circulating T cells. This hypothesis is supported by recent
findings indicating that patients with CTCL exhibit a
profound loss of T cell receptor repertoire complexity, which
could explain their severe immunosuppression (Yawalker et
al, 2003). Nevertheless, further studies with separated
malignant lymphocytes and reactive lymphocytes using
specific monoclonal antibodies capable of distinguishing
these two populations (Bagot et al, 2001) are needed to
reach a definite conclusion on this point.
FAK is a nonreceptor protein-tyrosine kinase that
indirectly localizes to sites of integrin-receptor clustering
through C-terminal-domain-mediated interactions with in-
tegrin-associated proteins such as paxillin and talin (Hil-
debrand et al, 1993; Chen et al, 1995; Tachibana et al, 1995;
Liu et al, 1999). Experiments using FAK-null cells (Owen
et al, 1999), FAK overexpression (Cary et al, 1998), and
dominant-negative FAK constructs (Gilmore and Romer,
1996) have established that FAK is essential for integrin-
stimulated migration. Neuropeptides, and more recently NT
through NT1 receptors, were reported to induce the
phosphorylation of FAK in lung cancer cells (Rozengurt,
1991; Leyton et al, 2002). Furthemore, bombesin was found
to cause reorganization of the actin cytoskeleton and the
assembly of focal adhesion plaques where both FAK and
paxillin are localized (Schaller et al, 1992; Hanks et al, 1992).
Here, we report that NT redistributes phospho-FAK and F-
actin in cells that migrate in response to the neuropeptide.
In addition, our unpublished results also indicate that
phospho-proline-rich/Ca2þ -activated tyrosine kinase (pyk-
2), which belongs to the family of FAK proteins, is
redistributed in a way similar to phospho-FAK by NT in
Cou-L CTCL cells. Moreover, we demonstrate that PI3-K
inhibitors inhibit cell migration and phospho-FAK relocaliza-
tion induced by NT through NT1 receptors. Extensive
studies of the role of PI3-K in the cytoskeletal changes
and cell migrations have been reported (Jime´nez et al,
2000). Finally, in agreement with the lack of NT chemoat-
tractant effect observed with atypical lymphocytes, we
show that the Sezary cell line Pno, which expresses NT1
receptor transcripts and which was previously reported to
bind significantly FITC-labeled NT (Ramez et al, 2001), fails
to relocalize phospho-FAK in the presence of NT.
In conclusion the results, summarized in Table I, show
fundamental differences between normal circulating lym-
phocytes and Sezary syndrome cells. Moreover, they show
that expression of NT1 receptor transcripts is not correlated
with cell migration to NT. Although all cells tested in these
studies were found to express NT1 receptors, their
chemotactic responses varied depending on the chemoat-
tractant used. Sezary cells and CD3-activated normal
lymphocytes failed to migrate to NT but still responded to
SDF-1a. Interestingly, similar abnormal T lymphocyte signal
transduction following engagement of various receptors on
Sezary cells has been reported (Fargnoli et al, 1997; Zhang
et al, 2000; Brender et al, 2001). Our results also show
differential responses to NT between the skin mycosis-
fungoides-derived cell line Cou-L and the blood Sezary-
syndrome-derived cell line Pno, which were both expanded
with IL-2. Thus, it will be important to determine whether
freshly isolated skin-derived malignant mycosis fungoides
cells migrate in response to NT. The ability to migrate to NT
might functionally distinguish Sezary from mycosis fun-
goides cells. Finally, the identification of alterations in the
signaling pathways following neuropeptide receptor trigger-
ing constitutes an additional step toward an understanding
of the molecular basis of the Sezary cells and normal
lymphocytes and between the different forms of CTCL.
Materials and Methods
Patients After informed consent and approval by an ethical
committee (CCPPRB, Henri Mondor, Cre´teil, France), we obtained
blood samples from Sezary syndrome patients with 20%–90%
atypical circulating CD3þ , CD4þ , CD8– cells determined by
cytomorphology. No patients had previously undergone che-
motherapy. Diagnosis of Sezary syndrome was based on clinical
criteria (erythroderma, pruritus, palmoplantar keratoderma, diffuse
adenopathies), cytomorphologic criteria including atypical circu-
lating cells, histologic data (cutaneous epidermotropic T cell
lymphoma), and detection of an identical T cell clone in the blood
and the skin by qualitative PCR DGGEg (Delfau-Larue et al, 1998).
Cells and cell lines PBMC from normal individuals and from
Sezary patients were isolated by the technique of Ficoll-Isopaque
(Pharmacia Fine Chemicals, Piscataway, NJ) density gradient
centrifugation, washed, and frozen in human serum plus 10%
dimethyl sulfoxide for later use. PBMC from normal individuals
were subsequently separated into monocytes and lymphocytes
using the monocyte isolation kit from Miltenyi Biotec (Bergisch
Gladbach, Germany). The isolated population corresponded to
nearly 95% CD14þ cells by flow cytometry analysis. CD14-
negative PBMC were then labeled with anti-CD4-FITC and anti-
CD8-PC5 purchased from Beckman-Coulter (Miami, FL) and
separated into CD4þCD8– and in CD8þCD4– cells using an EPICS
ELITE (Beckman-Coulter). PBMC from Sezary patients with 60% or
Table 1. Expression of NT1R transcripts and chemotactic responses of normal and Sezary lymphocytes
Cells Normal Sezary
Pno Cou-L Jurkat PBMC CD4þ activated PBMC CD4þ cells
Transcript
NT1R þ þ þ þ þ þ þ þ
Migration
NT  þ þ þ þ   
NTþSR48692 a   a a a a a
SDF-1a þ þ þ þ þ þ þ þ
aData not shown
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90% of CD4þ atypical cells were labeled with anti-CD4-FITC and
separated into CD4þ and CD4– lymphocytes. The separated cells
were reanalyzed by flow cytometry and corresponded to 100% of
the lymphocyte subset positively selected. Human CTCL malignant
cell lines Cou-L and Pno were established from the skin of a
transformed mycosis fungoides patient and from the peripheral
blood of a Sezary syndrome patient, respectively. They were
developed and maintained in culture as previously described
(Bagot et al, 1998; Poszepczynska et al, 2000). Cou-L is an IL-2-
dependent cell line that has a CD3þCD4þVb13þ phenotype,
whereas the Pno cell line has a CD3þVb22þCD4þCD8dimþ
phenotype and proliferates in response to both IL-2 and IL-7.
Both the Pno and Cou-L malignant cell lines were expanded with
IL-2 (50 U per mL) for this study. The leukemic cell line Jurkat was
mycoplasma-free and was expanded in culture medium consisting
of RPMI 1640 (Gibco, Paisley, UK) supplemented with 10% fetal
bovine serum (FBS), 2 mmol per L L-glutamine, penicillin (100 U
per mL), and streptomycin (100 mg per mL). CHO wild-type cells
were cultured in a-modified Eagle’s medium (a-MEM, Gibco)
supplemented with antibiotic and 5% FBS. CHO cells stably
expressing the human NT1 receptors were cultured in MEM with
Earle’s salts, L-gln, L-pro, pyruvate, antibiotic, and 10% dialyzed
FBS (Gibco).
Reagents NT and wortmannin were obtained from Sigma (Sigma-
Aldrich Chimie, Saint Quentin Fallavier, France) and LY294002 from
Biomol (Plymouth, MA) and were prepared following the manu-
facturers’ recommendations. The nonpeptide NT1 receptor an-
tagonist SR48692 produced by our laboratory (Gully et al, 1993;
1997) was dissolved at 1 mM in dimethyl sulfoxide (DMSO). Both
NT and SR48692 were stored at 201C in 50 mL aliquots. IL-7 (10
ng per mL) and IL-2 (50 U per mL) were produced by our
laboratory. Fractalkine was purchased from Sigma; SDF-1a and
RANTES were purchased from R&D Systems (Lille, France). Rabbit
polyclonal antibody reactive with (Tyr397)-phosphorylated FAK was
purchased from Biosource International (Camarillo, CA). Alexa
Fluor goat antirabbit Ig was purchased from Molecular Probes
(Eugene, OR).
Immunoﬂuorescence staining Cells were incubated for 5 or 10
min with medium without serum containing DMS0 (vehicle), NT (10,
50, 100, 250, or 500 nM), or SDF-1a (10, 100, or 400 ng per mL).
Both NT and the chemokine were diluted in medium without serum.
In some experiments the cells were first incubated 30 min with the
nonpeptide NT1 receptor antagonist SR48692 (500 nM) or each of
the PI3-K inhibitors wortmannin (100 nM) and LY294002 (50 mM)
before stimulation. The cells were then attached to glass slides
using a Shandon (Pittsburgh, PA) Cytospin centrifuge. After rinsing
in phosphate-buffered saline (PBS), cells were fixed in cold
methanol for 3 min, and permeabilized by two rinses in Tris-
buffered saline (TBS)Tween 20, purchased from DAKO (Trappes,
France). Slides were incubated for 1 h with anti(Tyr397)-phospho-
FAK 10 mg per mL, washed twice in TBSTween 20, and then
incubated for 45 min with the secondary antibody. For the
detection of F-actin, cells were fixed in 3% formaldehyde from
Merck (Darmstadt, Germany), washed in PBS, then permeabilized
for 2 min in 0.1% Triton-X100 (Sigma), and incubated with BODIPY-
phallacidin (Molecular Probes). After two rinses in TBSTween 20,
slides were mounted and cells were examined with a Leica
DMIRBE microscope (Rueil-Malmaison, France) and photo-
graphed using a Photometrics Quantix camera (Huntington Beach,
CA) and the Isee graphical programming system of Innovision
(Raleigh, NC).
Chemotaxis assays Cell migration was evaluated according to a
modification of the original technique described by Boyden (1962;
Delaire et al, 2001). Briefly, 24-well chambers with two compart-
ments separated by a polycarbonate filter of 5 mm pore size
(Costar, Corning, NY) were used. Aliquots of 100 mL of cell
suspensions (2  106 cells per mL) were deposited in the wells of
the upper compartments and 600 mL of medium alone or
containing NT or chemokines were placed into the lower wells of
the chamber for spontaneous mobility or chemotaxis assays,
respectively. For tests of inhibition, cells were preincubated at 371C
for 30 min in the presence of SR48693 (250 and 500 nM),
wortmannin (100 nM), or LY294002 (50 mM). The chambers were
incubated at 371C for 12 h. Cell migration was evaluated by
counting the total number of cells migrating toward the lower
compartment. Cell viability was determined using the trypan blue
exclusion test.
PCR experiments Total RNA was extracted from the cells
(5  106) using the acid guanidinium isothiocyanate phenol chloro-
form method (RNAzol B method). cDNA was prepared by standard
methods using reverse transcriptase and oligo-dT primer. PCR was
performed with two h-NT1R specific primers at position 2216
(backward, 50-GGG-CCC-CCA-GCT-TGC-CAG-30) and 1413 (for-
ward, 50-GGT-GAC-CAA-CGC-ACT-CTT-30) giving a PCR product
of 786 pb. The reaction cycle consisted of denaturation for 1 min at
941C, annealing for 1 min at 551C, and extension for 1 min at 721C,
and was repeated 35 times.
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